Study identifier:D419QC00007
ClinicalTrials.gov identifier:NCT04774380
EudraCT identifier:2020-005537-32
CTIS identifier:N/A
A Phase IIIb, Single-arm, Multi-center, International Study of Durvalumab in Combination with Platinum and Etoposide for the First Line Treatment of Patients with Extensive-stage Small Cell Lung Cancer (LUMINANCE)
Extensive-stage Small Cell Lung Cancer
Phase 3
No
Durvalumab, Cisplatin, Carboplatin, Etoposide
All
152
Interventional
18 Years - 130 Years
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Jul 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Durvalumab - (cisplatin or carboplatin) - Etoposide Participants will receive durvalumab dose A administered via intravenous (IV) infusion concurrently with platinum-based chemotherapy and etoposide every 3 weeks (q3w). Thereafter, durvalumab monotherapy will be continued every 4 weeks post-chemotherapy unless specific treatment discontinuation criteria are met. | - |